By Adam Gefvert, CFA : Achillion Pharmaceuticals (NASDAQ: ACHN ) is a biotech company that focuses on developing treatments for Hepatitis C (HCV). Most of the company's value is riding on the success of its nucleotide, ACH-3422. Research suggests that if trials show that this nucleotide works only
developing countries representing more than 100M people infected with hep C (54% of the global infected population). The Indian companies ..... manufacture of sofosbuvir or ledipasvir in combination with other chronic hep C medicines. Post your comment!
* Says licensed Hep C drug Sovaldi to 7 companies including Cipla Ltd, Mylan laboratories, Ranbaxy
the party on June 10 when it announced the lifting of the clinical hold on its hep C candidate sovaprevir imposed by the FDA and the initiation of patient dosing in a Phase 1 trial of ACH-3422 in hep C genotype 1 patients. Post your comment!
Immunotech Laboratories ( OTCPK:IMMB -16.7% ) completes Phase 1 and Phase 2 trials of its HIV/AIDS and Hepatitis C virus treatment ( ITV-1 ) in Bulgaria. It has also completed toxicity testing and pharmacokinetic analyses on animals. The firm is preparing its application for a permit to proceed to
(Adds analyst comment, background; updates share movement)
Aug 15 (Reuters) - Gilead Sciences Inc said an arbitration panel has ruled in its favor, rejecting patent infringement claims from Roche Holding AG, related to Gilead's hepatitis C drug, Sovaldi.
ARC-520 is being studied as a functional cure for hepatitis B ( Hep B). The compound showed great promise in pre-clinical proof ..... a Phase 2a efficacy and escalating dosing study with chronic Hep B patients in March of 2014 and completed earlier this summer
Holly Energy Partners reported second-quarter results on Aug. 5 that fell short of expectations, primarily due to decreased throughput volumes on
board and chairman and CEO of Holly Energy Partners L.P. Mike Jennings, CEO ..... has a 39% ownership stake in Holly Energy Partners , which owns and operates petroleum ..... the value in the ownership of HEP . Our fair value estimate implies